Roche Holding (RHO6) Price & Analysis

Compare

18 Followers

RHO6 Stock Chart & Stats

Day’s Range― - ―

52-Week Range€31.80 - €40.31

Previous CloseN/A

Volume0.00

Average Volume (3M)123.00

Market Cap

$228.33B

Enterprise Value€293.72B

Total Cash (Recent Filing)$17.32B

Total Debt (Recent Filing)$36.35B

Price to Earnings (P/E)22.9

Beta0.43

Next Earnings

Jan 29, 2026

EPS Estimate

1.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.49

Shares Outstanding5,620,501,500

10 Day Avg. Volume307

30 Day Avg. Volume123

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.29

Enterprise Value/Revenue4.78

Enterprise Value/Gross Profit6.46

Enterprise Value/Ebitda17.79

Forecast

1Y Price Target

$36.67

Price Target Upside3.74% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.

Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.

Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.

Bears Say

Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.

Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.

Roche Holding News

Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

3h ago

Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads

Shares of several pharmaceutical makers as well as those of major advertising agencies are in the spotlight on...

2d ago

AZN

Omnicom, WPP under pressure after Trump moves to regulate pharma ads

Shares of Omnicom (OMC) and WPP (WPP) are under pressure after President Trump signed a memorandum mandating pharma...

2d ago

AZN

BMY

Trump Trade: U.S. President signs new pharma order

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2d ago

AZN

Trump signs memorandum mandating pharma ads give more info on risks

U.S. President Donald Trump has signed a memorandum mandating that pharmaceutical advertisements increase the amount of information regarding...

3d ago

AZN

BMY

Alnylam price target raised to $470 from $450 at BMO Capital

BMO Capital raised the firm’s price target on Alnylam (ALNY) to $470 from $450 and keeps an Outperform...

4d ago

ALNY

CHRO

Genentech announces data from AVONELLE-X, SALWEEN studies of Vabysmo

Genentech, a member of Roche (RHHBY), announced new data from the AVONELLE-X and SALWEEN studies of Vabysmo, presented...

7d ago

CHRO

Roche receives EU CE mark for its Port Delivery Platform containing Susvimo

Roche (RHHBY) announced that it has received the EU CE mark for its Port Delivery Platform containing Susvimo,...

8d ago

CHRO

Oppenheimer says Olema collaboration with Pfizer could lead to bidding war

Oppenheimer analyst Matthew Biegler says the firm had a chance to speak with Olema Oncology (OLMA) management after...

9d ago

NVS

PFE

Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran

Roche (RHHBY) and Alnylam (ALNY) announced the decision to initiate a Phase 3 cardiovascular outcomes trial to evaluate...

13d ago

ALNY

CHRO

Royalty Pharma Stock (RPRX) Rises as it Seals $950M Cancer Royalties Deal with Amgen

Shares in Royalty Pharma ($RPRX) were higher today after snapping up a royalty interest in pharmaceutical group Amgen’s...

18d ago

ONC

AMGN

Roche Holding AG Faces Growth Challenges Amidst Competition and Regulatory Risks, Downgraded to Underweight

Morgan Stanley analyst Sarita Kapila downgraded the rating on Roche Holding AG to a Sell today, setting a...

1M ago

CHRO

Roche Holding AG’s Earnings Call Highlights Growth and Challenges

Roche Holding AG (($RHHBY)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

Roche Reports Strong Half-Year Growth in 2025

Roche Holding AG ( ($RHHBY) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

RHO6 FAQ

What was Roche Holding’s price range in the past 12 months?

Roche Holding lowest stock price was €31.80 and its highest was €40.30 in the past 12 months.

What is Roche Holding’s market cap?

Roche Holding’s market cap is $228.33B.

When is Roche Holding’s upcoming earnings report date?

Roche Holding’s upcoming earnings report date is Jan 29, 2026 which is in 139 days.

How were Roche Holding’s earnings last quarter?

Roche Holding released its earnings results on Jul 24, 2025. The company reported €1.491 earnings per share for the quarter, beating the consensus estimate of €1.445 by €0.045.

Is Roche Holding overvalued?

According to Wall Street analysts Roche Holding’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Roche Holding pay dividends?

Roche Holding does not currently pay dividends.

What is Roche Holding’s EPS estimate?

Roche Holding’s EPS estimate is 1.15.

How many shares outstanding does Roche Holding have?

Roche Holding has 5,620,501,500 shares outstanding.

What happened to Roche Holding’s price movement after its last earnings report?

Roche Holding reported an EPS of €1.491 in its last earnings report, beating expectations of €1.445. Following the earnings report the stock price went down -2.114%.

Which hedge fund is a major shareholder of Roche Holding?

Currently, no hedge funds are holding shares in DE:RHO6

Roche Holding Stock Smart Score

Neutral

Fundamentals

Return on Equity

31.98%

Trailing 12-Months

Asset Growth

11.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Roche Holding

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Roche Holding (RHO6) Earnings & Revenues

Historic Earnings Reports

RHO6 Company Deck

RHO6 Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call demonstrated strong financial performance and strategic advancements, particularly in the pharmaceutical segment with robust sales growth and significant pipeline developments. However, there were notable challenges, including the impact of China's pricing reforms on Diagnostics, safety concerns with Elevidys, and mixed trial results for some drugs.View all DE:RHO6 earnings summaries

RHO6 Stock 12 Month Forecast

Average Price Target

€36.67

▲(3.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"€31","33":"€33","35":"€35","37":"€37","39":"€39"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38.37867975,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€38.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.67296065,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€36.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.26152245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€33.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,33,35,37,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.115,34.44297536538462,34.770950730769236,35.098926096153846,35.42690146153846,35.75487682692308,36.0828521923077,36.41082755769231,36.738802923076925,37.06677828846154,37.39475365384616,37.72272901923077,38.050704384615386,{"y":38.37867975,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.115,34.311766203846155,34.50853240769231,34.70529861153846,34.90206481538462,35.09883101923077,35.295597223076925,35.49236342692308,35.68912963076923,35.88589583461538,36.08266203846154,36.279428242307695,36.47619444615385,{"y":36.67296065,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.115,34.04934788076923,33.98369576153846,33.918043642307694,33.852391523076925,33.786739403846155,33.721087284615386,33.65543516538462,33.58978304615385,33.52413092692308,33.45847880769231,33.39282668846154,33.32717456923077,{"y":33.26152245,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.263,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.203,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":34.637,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":34.789,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.511,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.654,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.433,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.589,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.83,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.225,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.115,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >